153 related articles for article (PubMed ID: 22391705)
1. Normal uptake of 68Ga-DOTA-TOC by the pancreas uncinate process mimicking malignancy at somatostatin receptor PET.
Jacobsson H; Larsson P; Jonsson C; Jussing E; Grybäck P
Clin Nucl Med; 2012 Apr; 37(4):362-5. PubMed ID: 22391705
[TBL] [Abstract][Full Text] [Related]
2. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.
Kroiss A; Putzer D; Decristoforo C; Uprimny C; Warwitz B; Nilica B; Gabriel M; Kendler D; Waitz D; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):514-23. PubMed ID: 23291643
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
[TBL] [Abstract][Full Text] [Related]
4. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE.
Velikyan I; Xu H; Nair M; Hall H
Nucl Med Biol; 2012 Jul; 39(5):628-39. PubMed ID: 22336375
[TBL] [Abstract][Full Text] [Related]
5. Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy.
de la Cueva L; Lloro P; Sangrós MJ; López Vélez L; Navarro P; Sarria L; Álvarez S; Abós D
Clin Transl Oncol; 2017 Jul; 19(7):915-920. PubMed ID: 28144828
[TBL] [Abstract][Full Text] [Related]
6. 99mTc-HYNIC-TOC increased uptake can mimic malignancy in the pancreas uncinate process at somatostatin receptor SPECT/CT.
Yamaga LY; Neto GC; da Cunha ML; Osawa A; Oliveira JC; Fonseca RQ; Nogueira SA; Wagner J; Funari MG
Radiol Med; 2016 Mar; 121(3):225-8. PubMed ID: 26558391
[TBL] [Abstract][Full Text] [Related]
7. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.
Gabriel M; Decristoforo C; Kendler D; Dobrozemsky G; Heute D; Uprimny C; Kovacs P; Von Guggenberg E; Bale R; Virgolini IJ
J Nucl Med; 2007 Apr; 48(4):508-18. PubMed ID: 17401086
[TBL] [Abstract][Full Text] [Related]
8. Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours?
Al-Ibraheem A; Bundschuh RA; Notni J; Buck A; Winter A; Wester HJ; Schwaiger M; Scheidhauer K
Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):2005-13. PubMed ID: 21792572
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
10. Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours.
Virgolini I; Gabriel M; Kroiss A; von Guggenberg E; Prommegger R; Warwitz B; Nilica B; Roig LG; Rodrigues M; Uprimny C
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2072-83. PubMed ID: 27174220
[TBL] [Abstract][Full Text] [Related]
11. Detection of pancreatic neuroendocrine tumors (PNET) using semi-quantitative [68Ga]DOTATOC PET in combination with multiphase contrast-enhanced CT.
Froeling V; Röttgen R; Collettini F; Rothe J; Hamm B; Brenner W; Schreiter N
Q J Nucl Med Mol Imaging; 2014 Sep; 58(3):310-8. PubMed ID: 25265251
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor based PET/CT imaging with 68Ga-DOTA-Nal3-octreotide for localization of clinically and biochemically suspected insulinoma.
Sharma P; Arora S; Karunanithi S; Khadgawat R; Durgapal P; Sharma R; Kandasamy D; Bal C; Kumar R
Q J Nucl Med Mol Imaging; 2016 Mar; 60(1):69-76. PubMed ID: 24740163
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors.
Hanaoka H; Tominaga H; Yamada K; Paudyal P; Iida Y; Watanabe S; Paudyal B; Higuchi T; Oriuchi N; Endo K
Ann Nucl Med; 2009 Aug; 23(6):559-67. PubMed ID: 19504168
[TBL] [Abstract][Full Text] [Related]
14. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
Madrzak D; Mikołajczak R; Kamiński G
Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography study on pancreatic somatostatin receptors in normal and diabetic rats with 68Ga-DOTA-octreotide: a potential PET tracer for beta cell mass measurement.
Sako T; Hasegawa K; Nishimura M; Kanayama Y; Wada Y; Hayashinaka E; Cui Y; Kataoka Y; Senda M; Watanabe Y
Biochem Biophys Res Commun; 2013 Dec; 442(1-2):79-84. PubMed ID: 24220338
[TBL] [Abstract][Full Text] [Related]
16. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?
Ezziddin S; Lohmar J; Yong-Hing CJ; Sabet A; Ahmadzadehfar H; Kukuk G; Biersack HJ; Guhlke S; Reichmann K
Clin Nucl Med; 2012 Jun; 37(6):e141-7. PubMed ID: 22614212
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
[TBL] [Abstract][Full Text] [Related]
19. Physiological Uptake in the Pancreatic Head on Somatostatin Receptor Scintigraphy Using [111In-DTPA]Octreotide: Incidence and Mechanism.
Brabander T; Teunissen J; Kwekkeboom D
Clin Nucl Med; 2017 Jan; 42(1):15-19. PubMed ID: 27775943
[TBL] [Abstract][Full Text] [Related]
20. Frequency and significance of physiological versus pathological uptake of 68Ga-DOTATATE in the pancreas: validation with morphological imaging.
Mapelli P; Tam HH; Sharma R; Aboagye EO; Al-Nahhas A
Nucl Med Commun; 2014 Jun; 35(6):613-9. PubMed ID: 24686250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
